Video

Dr. Abou-Alfa on Doxorubicin Plus Sorafenib in Liver Cancer

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, describes a study looking at sorafenib plus doxorubicin compared with doxorubicin alone in patients with advanced hepatocellular carcinoma (HCC).

The phase III randomized trial showed benefit in overall survival (OS), progression-free survival (PFS), and time to progression (TTP). Median OS was 13.7 months in the doxorubicin-sorafenib arm (95% CI, 8.9--not reached) and 6.5 months (95% CI, 4.5-9.9; P = .006) in the doxorubicin-placebo arm. PFS also showed benefit: 6.0 months (95% CI, 4.6-8.6) versus 2.7 months (95% CI, 1.4-2.8; P = .006). Median TTP was 6.4 months (95% CI, 4.8-9.2) compared to 2.8 months (95% CI, 1.6-5) (P = .02).

Abou-Alfa notes that research must be completed to determine whether the benefit is related to sorafenib or if true synergistic activity is taking place. The ASK1 molecule works well with a RAF kinase inhibitor such as sorafenib and is crucial for an anthracycline such as doxorubicin to cause apoptosis.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity